Trials / Completed
CompletedNCT01801137
The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium
A Multicentre Phase III Trial to Determine the Efficacy of RAD 001 (Everolimus, Afinitor) as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium Which Failed or Progressed After First Line Chemotherapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Hopital Foch · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study to determine the efficacy of Everolimus(Afinitor®) as third line therapy in patients with transitional cell carcinoma of the urothelium which failed or progressed after two lines of chemotherapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus (Afinitor®) |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2014-10-01
- Completion
- 2014-10-01
- First posted
- 2013-02-28
- Last updated
- 2016-06-21
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01801137. Inclusion in this directory is not an endorsement.